drugset / Trial / NCT00151775
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure
RandomizedParallel-groupDouble-blindTreatment
Summary
This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks.
Timeline
- Start
- 2005-05
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olmesartan medoxomil | Unknown | 0.3 mg/kg | — |
| Subject | Olmesartan medoxomil | Unknown | 0.6 mg/kg | — |
| Subject | Olmesartan medoxomil | Unknown | 2.5 mg | — |
| Subject | Olmesartan medoxomil | Unknown | 10 mg | — |
| Subject | Olmesartan medoxomil | Unknown | 40 mg | — |